SCHEMBL4674537

SCHEMBL4674537

O=C(C=C(O)c1nc[nH]n1)c1cc(Cc2ccccn2)n[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
ALDH1A1 P00352 3/20 0.36
RAB9A P51151 3/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
TSHR P16473 1/20 0.34
TACR3 P29371 1/20 0.34
MAPK1 P28482 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673691 0.84 PIN1 (0.38) PIN1SMN1; SMN2ALDH1A1RAB9AKDM4E
SCHEMBL4677813 0.83 CYP1A2 (0.32) ALDH1A1TACR3MAPK1HDAC3HDAC4
SCHEMBL4674678 0.83 HCAR3 (0.39) ALDH1A1RAB9AHTTKDM4EKMT2A
SCHEMBL4672954 0.82 PIN1 (0.43) PIN1SMN1; SMN2ALDH1A1RAB9AKDM4E
SCHEMBL4672128 0.80 ALPL (0.34) ALDH1A1KDM4EMAPK1HDAC3HDAC4
SCHEMBL4677798 0.80 ALPL (0.34)
SCHEMBL4674016 0.80 MAPT (0.38) RAB9AHTTKDM4EKMT2AMEN1
SCHEMBL4673085 0.80 HCAR2 (0.42) MAPK1POLB
SCHEMBL4674076 0.80 HRH4 (0.36) PIN1SMN1; SMN2ALDH1A1RAB9APKM
SCHEMBL4673283 0.79 KMT2A (0.37) SMN1; SMN2ALDH1A1HTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PIN1 323/4885SMN1; SMN2 4107/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.